Ernexa Therapeutics (ERNAW) Convertible Debt (2023 - 2024)
Ernexa Therapeutics (ERNAW) reported Convertible Debt of $32.0 million for Q3 2024, up 828.07% on a YoY basis from $3.5 million in Q4 2023, and up 260.17% quarter-over-quarter from $8.9 million in Q2 2024.
Ernexa Therapeutics (ERNAW) Convertible Debt (2023 - 2024) Analysis & Trends
Ernexa Therapeutics has reported Convertible Debt for 2 years, with the latest figure at $32.0 million in Q3 2024.
- For the quarter ending Q3 2024, Convertible Debt rose 828.07% year-over-year to $32.0 million; the trailing twelve-month figure through Sep 2024 stood at $32.0 million (up 828.07% YoY), and the FY2023 full-year result was $6.8 million, changed N/A from the prior year.
- Convertible Debt for Q3 2024 stood at $32.0 million, up from $8.9 million in the prior quarter.
- The five-year high for Convertible Debt was $32.0 million in Q3 2024, with the low at $3.5 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ernexa Therapeutics | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 32.04 Mn |
| Jun 30, 2024 | 8.90 Mn |
| Mar 31, 2024 | 8.01 Mn |
| Dec 31, 2023 | 6.77 Mn |
| Sep 30, 2023 | 3.45 Mn |